Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD-guided gemtuzumab ozogamicin consolidation in core-binding factor AML
jRCTs041200063Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2020
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of gemtuzumab ozogamicin and cytarabine in acute myeloid leukemia (AML) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: 2-year relapse-free survival. Started Dec 2020; status: active, not recruiting.
02
Drugs
gemtuzumab ozogamicincytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on jRCTs041200063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041200063.